Pages that link to "Q73393234"
Jump to navigation
Jump to search
The following pages link to The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy (Q73393234):
Displaying 35 items.
- Targeted therapy in advanced bladder cancer: what have we learned? (Q27009469) (← links)
- Multimodal management of muscle-invasive bladder cancer (Q27011624) (← links)
- Role of angiogenesis in urothelial bladder carcinoma (Q28080330) (← links)
- Preliminary Analysis of the Expression of Selected Proangiogenic and Antioxidant Genes and MicroRNAs in Patients with Non-Muscle-Invasive Bladder Cancer (Q28390776) (← links)
- Recursive partitioning for tumor classification with gene expression microarray data (Q30653098) (← links)
- Spotlight on differentially expressed genes in urinary bladder cancer. (Q33869194) (← links)
- The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma (Q34365135) (← links)
- Vascular endothelial growth factor, p53, and the H-ras oncogene in Egyptian patients with bladder cancer (Q34390864) (← links)
- Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer (Q34826155) (← links)
- Angiogenesis in urinary bladder carcinoma as defined by microvessel density (MVD) after immunohistochemical staining for Factor VIII and CD31. (Q34849883) (← links)
- Tumour angiogenic activity and vascular survival ability in bladder carcinoma (Q35587443) (← links)
- Clinical significance of vascular endothelial growth factor expression and neovascularization in colorectal carcinoma (Q36179792) (← links)
- Combination of molecular alterations and smoking intensity predicts bladder cancer outcome: a report from the Los Angeles Cancer Surveillance Program (Q36589325) (← links)
- Role of the angiogenic components, VEGFA, FGF2, OPN and RHOC, in urothelial cell carcinoma of the urinary bladder (Q36642294) (← links)
- Intense inflammation in bladder carcinoma is associated with angiogenesis and indicates good prognosis (Q36646472) (← links)
- Novel strategies for treating relapsed/refractory urothelial carcinoma (Q36995686) (← links)
- Growth factors and receptors as prognostic markers in urothelial carcinoma (Q37119228) (← links)
- Targeting angiogenesis in bladder cancer (Q37428195) (← links)
- Imaging angiogenesis of genitourinary tumors. (Q37677553) (← links)
- New Strategies in Muscle-Invasive Bladder Cancer: On the Road to Personalized Medicine (Q37854285) (← links)
- The route to personalized medicine in bladder cancer: where do we stand? (Q38337192) (← links)
- Targeting Signaling Transduction Pathways in Bladder Cancer (Q38608540) (← links)
- A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, an (Q38732403) (← links)
- Photodynamic therapy involves an antiangiogenic mechanism and is enhanced by ferrochelatase inhibitor in urothelial carcinoma (Q39182427) (← links)
- Endothelin-A-receptor antagonism with atrasentan exhibits limited activity on the KU-19-19 bladder cancer cell line in a mouse model (Q39853377) (← links)
- Predicting response of bladder cancers to gemcitabine and carboplatin neoadjuvant chemotherapy through genome-wide gene expression profiling (Q42715876) (← links)
- FGF2-mediated reciprocal tumor cell-endothelial cell interplay contributes to the growth of chemoresistant cells: a potential mechanism for superficial bladder cancer recurrence (Q51675463) (← links)
- Expression of Minichromosome Maintenance Proteins (MCM) and Cancer Prognosis: A meta-analysis. (Q52714395) (← links)
- Effect of mitomycin C on concentrations of vascular endothelial growth factor and its receptors in bladder cancer cells and in bladders of rats intravesically instilled with mitomycin C (Q54654144) (← links)
- Analyses of publicly available genomics resources define FGF-2-expressing bladder carcinomas as EMT-prone, proliferative tumors with low mutation rates and high expression of CTLA-4, PD-1 and PD-L1 (Q56894473) (← links)
- Molecular Predictors of Complete Response Following Neoadjuvant Chemotherapy in Urothelial Carcinoma of the Bladder and Upper Tracts (Q64260619) (← links)
- Neoadjuvant chemotherapy for bladder cancer (Q79370791) (← links)
- Clinical relevance of serum angiogenic activity in patients with transitional cell carcinoma of the bladder (Q81304392) (← links)
- Microvessel density as a prognostic marker in bladder carcinoma: correlation with tumor grade, stage and prognosis (Q81556628) (← links)
- Emodin inhibits the proliferation and invasion of bladder cancer cells via down-regulating Notch1 (Q92840618) (← links)